What is Caristo Diagnostics?
Founded in 2018, Caristo Diagnostics is an Oxford, UK-based biotechnology company which specializes in cardiac and vascular disease diagnostics and risk prediction. The company operates at the intersection of advanced medical imaging and artificial intelligence, developing tools that provide clinicians with actionable insights into patient cardiovascular health. By identifying high-risk patients earlier than traditional methods, Caristo Diagnostics aims to reduce the incidence of major adverse cardiovascular events. Its market position is bolstered by its deep integration with the Oxford research ecosystem, allowing it to translate academic breakthroughs into scalable, enterprise-level diagnostic solutions that address significant unmet needs in global healthcare.
How much funding has Caristo Diagnostics raised?
Caristo Diagnostics has raised a total of $16.3M across 1 funding round:
Series A
$16.3M
Series A (2023): $16.3M with participation from Oxford Investment Consultants, Oxford Sciences Enterprises, and BGF
Key Investors in Caristo Diagnostics
Oxford Investment Consultants
Oxford Investment Consultants partners with extraordinary founders to transform scientific research into innovative products that tackle significant global challenges, focusing on companies from leading UK research institutions.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company created to found, fund and build transformational businesses via a unique partnership with the University of Oxford.
BGF
BGF is an active and influential investor in small and mid-sized businesses in the UK, supporting a range of growing companies across every region and sector of the economy.
What's next for Caristo Diagnostics?
Looking ahead, Caristo Diagnostics is poised to leverage its recent capital injection to broaden its clinical validation studies and pursue international market expansion. The strategic focus will likely center on integrating its diagnostic platform into standard clinical workflows, thereby increasing adoption among healthcare providers and hospital networks. As the company matures, the emphasis will shift toward long-term value creation through the commercialization of its risk prediction technology, potentially setting a new standard for preventative cardiovascular care. The firm's ability to maintain its technological edge while scaling its operational infrastructure will be the primary determinant of its success in the competitive biotech landscape.
See full Caristo Diagnostics company page
